OBJECTIVES: The aim of this study is to review the utilisation of the BRAF inhibitors vemurafenib (V) and dabrafenib (D) in Ireland. METHODS: Anonymised data from the Primary Care Reimbursement Service (PCRS) database from March 2013 (first availability of V) to December 2015 was extracted and reviewed. The database includes details of the patient administrative region, gender, date of birth, and the date and cost of each claim. Data analysis was conducted using Microsoft Excel 2010 Version 14.0.7116.5000 and R version 3.2.3. Bootstrapping was used to estimate the cost per patient. RESULTS: A total of 494 claims for a BRAF inhibitor were made from March 2013-December 2015; 55.3% for V compared to 44.7% for D. Claims were made for 99 unique claimants. 53.1% of incident claimants were male. The number of incident cases annually was 21, 36 and 42 in the years 2013-2015 respectively. Market share of incident patients declined for V to 22.4% following the introduction of D in September 2014. The mean number of claims per patient for both agents was 4.3. The mean cost per patient was €27,185.22 for D and €36,129.49 for V. The median time to treatment discontinuation (TTD) for V was 78 days (95% CI 47, 128), compared to 157 days CONCLUSIONS: There has been significant uptake of BRAF inhibitors since their introduction in March 2013. Reimbursement of D resulted in a significant decline in market share for V. The longer TTD with D is most likely due to concomitant use with the MEK inhibitor trametinib, available via a compassionate access program. Median TTD with V is similar to that seen in pivotal registration trials.